

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA BIOTECH SERVICES HOLDINGS LIMITED**

**中國生物科技服務控股有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

### **GRANT OF SHARE OPTIONS**

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”, which together with its subsidiaries, the “**Group**”) pursuant to Rule 23.06A of the Rules (the “**GEM Listing Rules**”) Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The board (the “**Board**”) of directors (the “**Directors**”, and each a “**Director**”) of the Company is pleased to announce that on 2 September 2020, the Company has granted to an executive director of the Company (the “**Grantee**”), subject to acceptance by the Grantee, 9,660,000 share options (the “**Share Options**”, each a “**Share Option**”) to subscribe for up to a total of 9,660,000 ordinary shares of nominal value of HK\$0.10 each (the “**Shares**”, each a “**Share**”) in the share capital of the Company under its share option scheme adopted on 29 May 2014.

A summary of the grant of the Share Options is set out below:

Date of grant:	2 September 2020 (the “ <b>Date of Grant</b> ”)
Exercise price for each Share Option:	HK\$2.00, which is higher than: <ul style="list-style-type: none"><li>(i) the closing price of HK\$1.53 per Share as quoted in the daily quotation sheet of the Stock Exchange on the Date of Grant;</li><li>(ii) the average closing price of HK\$1.54 per Share as quoted in the Stock Exchange’s daily quotation sheets for the five business days immediately preceding the Date of Grant; and</li><li>(iii) the nominal value of the Share.</li></ul>
Number of Share Options granted:	9,660,000 Shares Options, each Share Option entitling the Grantee to subscribe for one Share
Closing price of the Shares on the Date of Grant:	HK\$1.53 per Share
Validity period of the Share Options:	The Share Options are valid commencing from the Date of Grant until the end of the respective exercisable periods, among which: <ul style="list-style-type: none"><li>(i) 3,220,000 Share Options granted to the Grantee are exercisable from 2 September 2021 to 1 September 2022;</li><li>(ii) 3,220,000 Share Options granted to the Grantee are exercisable from 2 September 2022 to 1 September 2023; and</li><li>(iii) 3,220,000 Share Options granted to the Grantee are exercisable from 2 September 2023 to 1 September 2024.</li></ul>

All Share Options to subscribe for up to 9,660,000 Shares were granted to Mr. He Xun, who is an executive Director, details of which are set out as follows:

<b>Name of Grantee</b>	<b>Position held with the Company</b>	<b>Number of Shares which may be issued upon exercise of the Share Options</b>
Mr. He Xun	Executive Director	9,660,000

The grant of Share Options to Mr. He Xun has been approved by the independent non-executive Directors in accordance with Rule 23.04(1) of the GEM Listing Rules.

Save for being an executive Director, the Grantee is not a chief executive or substantial shareholder of the Company, or any of their respective associates (as defined under the GEM Listing Rules) of any of them.

By order of the Board  
**China Biotech Services Holdings Limited**  
**Liu Xiaolin**  
*Co-Chairman and Executive Director*

Hong Kong, 2 September 2020

*As at the date of this announcement, the board of Directors comprises six executive Directors, namely, Mr. Liu Xiaolin (Co-Chairman), Mr. Yao Michael Yi (Co-Chairman), Mr. He Xun, Mr. Huang Song, Mr. Leung Pak Hou Anson and Mr. Wang Zheng; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company information” page of the GEM website at [www.hkgem.com](http://www.hkgem.com) for at least 7 days from the date of its publication and on the website of the Company at [www.cbshhk.com](http://www.cbshhk.com).*